Literature DB >> 16415520

An asymptomatic heterozygous female with fabry disease: implications for enzyme replacement therapy.

Shin-ichiro Inagaki1, Makoto Migita, Mari Hayakawa, Atushi Fujita, Junko Yoshida, Masamichi Ishizaki, Masaharu Kotani, Hitoshi Sakuraba, Takashi Shimada, Mutsumi Murakami, Yoshitaka Fukunaga.   

Abstract

We report an asymptomatic female with Fabry disease immunohistochemically diagnosed by renal biopsy. She was initially diagnosed as having nephrotic syndrome, and renal biopsy was performed for pathological diagnosis. The renal specimen revealed non-specific findings (minor glomerular abnormalities) for nephrotic syndrome. Numerous laminated bodies in glomerular epithelial cells in electron microscopic findings and accumulations of ceramidetrihexoside immunohistochemically were observed and she was diagnosed with Fabry disease. However, no other laboratory data or clinical findings supported the diagnosis of Fabry disease. Since the efficacy of recombinant human alpha-galactosidase replacement therapy in this disease has been reported, whether enzyme replacement therapy for subclinical Fabry female patients is indicated or not is an important issue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16415520     DOI: 10.1272/jnms.72.387

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  2 in total

1.  Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review.

Authors:  Hironobu Fujisawa; Yosuke Nakayama; Shoichiro Nakao; Ryo Yamamoto; Yuka Kurokawa; Nao Nakamura; Akiko Nagata; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba; Kei Fukami
Journal:  BMC Nephrol       Date:  2019-12-17       Impact factor: 2.388

2.  Sudden onset of nephrotic syndrome in an asymptomatic Fabry patient: a case report.

Authors:  Ruixiao Zhang; Zeqing Chen; Yanhua Lang; Shihong Shao; Yan Cai; Qingqing You; Yan Sun; Sai Wang; Xiaomeng Shi; Zhiying Liu; Wencong Guo; Yue Han; Leping Shao
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.